MedPath

The effect of omega-3 fatty acid supplementation on oxidative stress in continuous ambulatory peritoneal dialysis patients

Not Applicable
Conditions
End Stage Renal Disease.
End Stage Renal Disease
Registration Number
IRCT201212142417N10
Lead Sponsor
Vice Chancellor for Research, Isfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
90
Inclusion Criteria

1)Clinically stable patients without serious disease.
2)continuous ambulatory peritoneal dialysis (CAPD) for at least 3 months.
3)hypertension stage 1(according to JNC VII) or under treatment.
Exclusion criteria: 1)history of steatorrhea.
2) malignancy.
3) thrombocytopenia (PLT<100000/mm3).
4) abnormal coagulation profile.
5)need for anticoagulation therapy.
6)psychosomatic disorders.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Reduced gluthation. Timepoint: Begining of the study, after 6 weeks. Method of measurement: ELISA kit, U/mL.;Srum superoxide dismutase. Timepoint: Begining of the study, after 6 weeks. Method of measurement: ELISA kit, U/mL.
Secondary Outcome Measures
NameTimeMethod
Serum Iron. Timepoint: Begining of the study, after 6 weeks. Method of measurement: ELISA kit, mg/dL.;Serum ferritin. Timepoint: Begining of the study, after 6 weeks. Method of measurement: ELISA kit, mg/dL.;Low density lipoprotein(LDL). Timepoint: Begining of the study, after 6 weeks. Method of measurement: mg/dL.;High density lipoprotein (HDL). Timepoint: Begining of the study, after 6 weeks. Method of measurement: mg/dL.;Triglyceride. Timepoint: Begining of the study, after 6 weeks. Method of measurement: mg/dL.;Cholesterol. Timepoint: Begining of the study, after 6 weeks. Method of measurement: mg/dL.
© Copyright 2025. All Rights Reserved by MedPath